March 2021 – An international syrup producer has awarded the contract for the extension and upgrade of its existing wastewater treatment plant at the production site in Kuala Lumpur, Malaysia, to the plant engineering company WEHRLE, based in Southern Germany.
TEVA – one of the world’s leading ten manufacturers of pharmaceuticals and owner of RATIOPHARM since 2010, as well as global market leader for generics – is investing approximately € 500 million for the large-scale production of state-of-the-art biotechnological active ingredients in Southern Germany.
In the greater Kuala Lumpur area, Malaysia’s largest waste management company, Kualiti Alam Sdn. Bhd, operates a landfill for the disposal of residual materials from several waste management companies. Due to the wide range and high degree of contamination of the residues and concentrates, also from the industry, the leachate of this landfill is very complex and difficult to treat.
The pandemic brings along new challenges, like, for example, the commissioning of state-of-the-art wastewater treatment plants in distant regions in times of travel restrictions: another task that WEHRLE has successfully mastered!
Pharmaceutical wastewater treatment expert WEHRLE from Germany predicts a good year 2021 for its business: “In the past years we have shown how effectively and reliably wastewater from drugs production can be treated – with compact treatment plants that eliminate and adsorb Trace Organic Contaminants respectively Active Pharmaceutical Ingredients efficiently at low operation costs. At the moment we see three development vectors that influencing our business of effluent treatment in the pharma industry:
The plant constructor WEHRLE with headquarters in Emmendingen in the South-West of Germany has obtained the contract for the design, construction and commissioning of a wastewater treatment plant for the treatment of highly loaded leachate from a municipal solid waste landfill in Jombang on the Indonesian island of Java.
With the change of the fertilizer regulation, the spreading and use of agricultural fertilizers is further limited. Farmers and biogas plant operators are often left with only costly temporary storage and expensive external disposal since the processes currently available on the market do not meet the requirements and involve high operating costs.
Environmentalists have been crying hoarse for long over the potential risks of pharmaceutical pollution. With water playing an integral part in the pharmaceutical manufacturing lifecycle, active pharmaceutical ingredients in wastewater, when discharged to the environment, may lead to the creation of multi-resistant germs in rivers and lakes. Treating pharmaceutical wastewater proves to be a challenge, and pharma producers are under the radar to contribute to improved water stewardship and take concrete measures to eliminate contaminants from their production wastewater. Against this backdrop, the German-based WEHRLE-WERK, with profound expertise in treating complex wastewater from the production of pharmaceutical drugs, can help pharmaceutical companies achieve this reliably and cost-effectively.
In some cases, the installed SBR process does not suffice to achieve the required treatment objectives. There is a variety of possible reasons: changes in the characteristics of the actual wastewater compared to the ones considered in the design (concentrations, flow rate), modification of the discharge requirements, incorrect process design, etc.